Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Session Icons
Live Streamed
On Demand
Favorite
Facebook
Tweet
Print
Prachi Nair, BS
Merck & Co., Inc.
Disclosure(s): Merck & Co., Inc.: Stocks/Bonds (Private Company)
Poster(s):
(P-445) Susceptibility and molecular characterization of isolates from a Phase 2/3, open-label, randomized, active-controlled clinical trial evaluating the safety and efficacy of imipenem/cilastatin/relebactam (IMI/REL) in pediatric participants with gram-negative (GN) bacterial infection
Monday, October 20, 2025
12:15 PM - 1:30 PM
US ET
